Immuneering reports Q1 net loss $14.3M; Phase 2a data for IMM-1-104 expected in 2024

Immuneering Corp

2024-Q1 EPS reported -$0.49

Net loss $14.3M ($0.49/share) vs $13.6M ($0.51) Q1 2023; R&D expense $11.2M up from $10.2M.
Phase 1 data for IMM-1-104 shows well-tolerated safety; target lesion regression in >50% of patients at 320mg.
First patient dosed in Phase 2a of IMM-1-104; initial data from multiple arms expected in 2024.
First patient dosed in Phase 1/2a of IMM-6-415 (RAF/RAS mutations); initial PK/PD/safety data expected 2024.
FDA Fast Track designation for IMM-1-104 in pancreatic cancer; cash $71.3M expected to fund operations into H2 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immuneering Corp reported the first quarter ended March 31, 2024 results: net income Net loss attributable to common stockholders was $14.3 million, or $0.49 per share, EPS $0.49 per share.

Period: the first quarter ended March 31, 2024
Net income: Net loss attributable to common stockholders was $14.3 million, or $0.49 per share
EPS: $0.49 per share
Result: reported results

Exact text from the filing

Immuneering Corporation (the “Company”) announced its financial results for the quarter ended March 31, 2024

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001790340-24-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.